Insmed Incorporated
(Public, NASDAQ:INSM) Watch this stockFind more results for
INSM
Advertisement
Events
Nov 6, 2009
Q3 2009 Earnings Release
|
More events from AOL Finance »
|
Key stats and ratios
| Q3 (Sep '09) | 2008 | |
| Net profit margin | -6.06% | -133.92% |
| Operating margin | -30.87% | -123.18% |
| EBITD margin | - | -114.27% |
| Return on average assets | -0.48% | -129.17% |
| Return on average equity | -0.50% | -361.62% |
| Employees | 97 | - |
Address
8720 Stony Point Parkway
Richmond, VA 23235
United States - Map
+1-804-5653000 (Phone)
+1-804-8286894 (Fax)
Richmond, VA 23235
United States - Map
+1-804-5653000 (Phone)
+1-804-8286894 (Fax)
Website links
Company website:
http://www.insmed.com/
http://www.insmed.com/
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Insmed Incorporated discussions
View all discussions »Description
Insmed Incorporated (Insmed) is a development stage biopharmaceutical company specializing in recombinant protein drug development. The Company also engaged the services of RBC to act as financial advisor. On March 31, 2009, the Company completed the sale of its follow-on biologics assets to Merck & Co., Inc. (Merck).
Officers and directors
| Melvin Sharoky M.D. | Chairman of the Board | |
| Kevin P. Tully | Chief Financial Officer, Executive Vice President | |
| Glen Kelley | Vice President - Regulatory Affairs | |
| Steve Glover | Chief Business Officer | |
| Kenneth G. Condon | Director | |
| Graham K. Crooke | Director | |
| Steinar J. Engelsen M.D. | Director | |
| Randall W. Whitcomb M.D. | Director | |
| Dennis M. Lanfear | Director |